Assessment of National Coverage and Out-of-Pocket Costs for Sacubitril/Valsartan Under Medicare Part D.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 31290933.
- Also identified by DOI 10.1001/jamacardio.2019.2223 and PMC identifier 6624798.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This study examines the insurance coverage and out-of-pocket costs to Medicare beneficiaries for the angiotensin receptor–neprilysin inhibitor sacubitril/valsartan.
Medical subject headings
- Aminobutyrates
- Angiotensin Receptor Antagonists
- Health Expenditures
- Heart Failure
- Insurance Coverage
- Medicare Part D
- Tetrazoles